NCT05586906 Noninvasive Early Detection of Lung Allograft Dysfunction After Lung Transplantation With Multiple Breath Washout Test
| NCT ID | NCT05586906 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Zurich |
| Condition | Chronic Rejection of Lung Transplant |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2023-03-01 |
| Primary Completion | 2024-04-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2023-03-01 with a primary completion date of 2024-04-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic rejection, more commonly called bronchiolitis obliterans syndrome (BOS), is the leading cause of death beyond the first year post lung transplantation. The diagnosis of BOS is typically made by clinical, physiological, and radiographic parameters. Early detection would be desirable since it allows treatment modification to stop or delay the process. In the last few years there has been a growing interest in lung clearance index (LCI), a measure of lung physiology derived from multiple breath washout tests. LCI is derived from Multiple Breath Washout (MBW) tests. Early detection of BOS with LCI measurement will allow the investigators early recognition of this chronic rejection form and with early institution of the enhanced treatment survival will increase. All paticipants who underwent bilateral lung transplantation at Zurich University Hospital will be included. The measurement will be done 3 months after lung transplantation. Approximately 90 paticipants will be included. The follow-up will be 5 years. If the investigators could detect the development of BOS with this novel method before the clinical deterioration (fall in lung function) the investigators can start the available treatment options before irreversible damage occurs. This might increase overall survival in the study cohort.
Eligibility Criteria
Inclusion Criteria: * All recipients who underwent bilateral lung transplantation at Zurich University Hospital will be included. Exclusion Criteria: * Retransplantation
Contact & Investigator
Carolin Steinack, MD
PRINCIPAL INVESTIGATOR
University of Zurich
Frequently Asked Questions
Who can join the NCT05586906 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Rejection of Lung Transplant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05586906 currently recruiting?
Yes, NCT05586906 is actively recruiting participants. Contact the research team at carolin.steinack@usz.ch for enrollment information.
Where is the NCT05586906 trial being conducted?
This trial is being conducted at Zurich, Switzerland.
Who is sponsoring the NCT05586906 clinical trial?
NCT05586906 is sponsored by University of Zurich. The principal investigator is Carolin Steinack, MD at University of Zurich. The trial plans to enroll 90 participants.